These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11847893)

  • 1. [Stress intolerance in diastolic dysfunction. A case for AT1 blocker?].
    MMW Fortschr Med; 2002 Jan; 144(1-2):69. PubMed ID: 11847893
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypertension plus left ventricular hypertrophy. Prognosis can now be significantly improved].
    Einecke D
    MMW Fortschr Med; 2002 Apr; 144(14):4-5. PubMed ID: 12014276
    [No Abstract]   [Full Text] [Related]  

  • 3. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

  • 4. [J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)].
    Yamamoto K; Hori M
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():513-5. PubMed ID: 17511101
    [No Abstract]   [Full Text] [Related]  

  • 5. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
    MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.
    Warner JG; Metzger DC; Kitzman DW; Wesley DJ; Little WC
    J Am Coll Cardiol; 1999 May; 33(6):1567-72. PubMed ID: 10334425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
    Schmieder RE; Schneider MP
    MMW Fortschr Med; 2002 Oct; 144(42):45-6. PubMed ID: 12533997
    [No Abstract]   [Full Text] [Related]  

  • 9. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
    MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results from the LIFE study: promising effects of new hypertensive agents].
    Nilsson P; Kahan T
    Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
    [No Abstract]   [Full Text] [Related]  

  • 11. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
    MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LIFE study--still-blinded results show promise.
    Cardiovasc J S Afr; 2001; 12(2):123-4. PubMed ID: 11474698
    [No Abstract]   [Full Text] [Related]  

  • 16. [In heart diseases, differential hypertension therapy].
    Werner N; Böhm M
    MMW Fortschr Med; 2003 Mar; 145(11):45-8. PubMed ID: 12688196
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertensive pulmonary oedema is due to diastolic dysfunction.
    Little WC
    Eur Heart J; 2001 Nov; 22(21):1961-4. PubMed ID: 11603900
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is one antihypertensive agent as good as another?].
    Trenkwalder P
    MMW Fortschr Med; 2002 Nov; 144(45):41-2. PubMed ID: 12534060
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.